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Chimeric antigen receptor (CAR) T cell therapy is an emerging cancer treatment that has 
shown remarkable success in the treatment of B cell malignancies. However, this therapy still 
has the potential to cause severe toxicities or poor treatment responses in some patients. An 
imaging tool for tracking CAR-T cells could provide important patient-specific data on CAR-
T cell fate. In chapter 2, fluorine-19 magnetic resonance imaging (19F MRI) was evaluated as 
a method to track the location of 19F perfluorocarbon (PFC) labeled CAR-T cells non-
invasively in a mouse model of B cell leukemia. We show for the first time that PFC labeled 
CAR-T cells can be detected with a 3 Tesla clinical MR scanner and that PFC labeled CAR-
T cells show no significant difference in treatment response compared to unlabeled CAR-T 
cells as evaluated with bioluminescence imaging. Chapter 3 summarizes the study and 
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Summary for Lay Audience 
Chimeric antigen receptor T (CAR-T) cell therapy involves taking immune cells from a 
patient’s blood, reprogramming them to bind and kill cancer cells, and then injecting them 
back into the patient. This treatment has shown a lot of success in patients battling blood 
cancers such as leukemia, but current therapies still face problems such as harmful side 
effects and ineffective treatment of solid tumours. My project is to implement imaging 
techniques to track the fate of CAR-T cells after they have been injected into the body. Our 
technique will use fluorine-19 magnetic resonance imaging to allow us to see the location of 
the cells over time. Our methods will be useful for learning more about the negative 
treatment responses to CAR-T cell therapy and for building and assessing new CAR-T cell 
therapies that are safer and more effective against cancer. Importantly, this CAR-T cell 
tracking method should be highly translatable for use in patients receiving CAR-T cell 
therapies. This may eventually allow doctors to determine if the therapy will be effective at 
earlier time points so that they can continue or change the treatment plan, to better determine 
if a patient will have harmful side effects, as well as to better understand why the treatment 
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Chapter 1  
1 Introduction  
This thesis develops and advances methods for tracking CAR-T cell therapies using 
fluorine-19 (19F) magnetic resonance imaging (MRI) in a mouse model of B cell 
leukemia. The introductory chapter discusses B cell malignancies, T cell therapies, proton 
(1H) MRI and 19F MRI, and bioluminescence imaging (BLI) techniques for cell detection. 
The purpose of the introductory chapter is to provide an introduction and motivation for 
the research project presented in this thesis. 
1.1 Motivation and Overview  
Cancer is a devastating disease with over 617 Canadians diagnosed every day1. Current 
standard of care cancer treatments have improved patient outcomes in many cases, but 
there is still a large proportion of patients that do not survive for more than 5 years after 
their initial diagnosis. Cell-based immunotherapies are a relatively newer way to treat 
cancer by taking advantage of the natural functions of viable immune cells to target and 
kill cancer cells. These therapies often aim to boost the immune system’s response to 
cancer by having immune cells travel to cancer sites and mount an anti-tumor immune 
response. Chimeric antigen receptor (CAR) T cell therapies in particular have shown 
tremendous potential in patients leading to increased excitement about the potential for 
cell therapies to be a powerful option to treat many cancer subtypes2,3. Unfortunately, 
these therapies still have a tendency to cause unwanted and sometimes serious side 
effects. In addition, some patients with blood cancers still show weak or no response to 
CAR-T cells and they are still showing disappointing results against solid tumours. 
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Current cell therapy monitoring in clinical trials relies heavily on blood tests and indirect 
measures of tumour size over time. These measures are unable to provide any 
information on the biodistribution of therapeutic cells or the number of cells in various 
important organs during treatment. Imaging methods to detect the locations and number 
of cells in the body would be extremely valuable for learning about therapeutic cell 
behaviours during negative side effects and treatment outcomes.  
In this thesis, 19F MRI is used to detect CAR-T cells over time after intratumoural 
administration. Chapter 1 provides an overview of the background and motivation 
relevant to the work presented in this thesis. Chapter 2 examines the use of 19F MRI to 
detect perfluorocarbon (PFC) labeled CAR-T cells in a mouse model of B cell leukemia 
using a 3 Tesla (T) clinical scanner. It also compares the treatment response in mice 
administered PFC labeled (PFC+) CAR-T cells compared to mice that received unlabeled 
CAR-T cells using BLI. Chapter 3 summarizes the work in this thesis and its 
significance, expands on the limitations of this work, and discusses future work related to 
the results presented in this thesis.  
1.2 B Cell Malignancies  
Hematological (blood) cancer, including B cell malignancies, are the fourth most 
commonly diagnosed cancer type in Canada4. Additionally, B cell malignancies are 
starting to affect more Canadians each year as the prevalence of these cancers increased 
by 25% between 2014 and 2016. These cancers are particularly devastating as they are 
one of the most common cancers found in children5. B cell malignancies are 
characterized by their origin in B lymphocytes and are often referred to as “liquid 
cancers” due to their occurrence in the blood and lymph. B cells are an important 
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leukocyte population in the body that protect against pathogens by producing antibodies 
and releasing cytokines6. B cell malignancies develop when B cells begin to expand 
rapidly and continue to grow past their normal life cycle, leading to the crowding of 
healthy cells. Patients often experience fever, frequent infections, and fatigue due to the 
accumulation and improper functioning of B cells in their body7. B cell malignancies are 
subdivided into B cell leukemia and B cell lymphoma based on the characteristics of the 
disease.  
1.2.1 B Cell Leukemia 
B cell leukemia subtypes usually start in the bone marrow and are found in the blood, 
bone marrow, and spleen of patients8,9. The two main types of B cell leukemias are B cell 
acute lymphoblastic leukemia (ALL) and B cell chronic lymphocytic leukemia (CLL). 
They are classified according to their rate of growth and their origin in the body. Chronic 
lymphocytic leukemia is characterized by abnormal mature B cell behaviour in the blood 
and develops more slowly10. In comparison, acute lymphocytic leukemia develops more 
quickly as it is characterized by genetic mutations in immature B cells that cause them to 
stop maturing and continually proliferate11.  
When patients present with symptoms such as bone pain, bleeding gums or nosebleeds, 
fever, or frequent infections they may be tested for leukemia. Leukemia is most often 
diagnosed using blood tests or bone marrow biopsies. There are approximately 6 000 new 
diagnoses of leukemia per year in Canada alone. Staging for ALL is dependent on the 
maturity of the B cell and staging for CLL is based on the Rai system12. The Rai system 
for CLL is dependent on the number of cancer cells in the blood, the degree to which the 
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spleen and lymph nodes are involved, and whether the patient has developed co-
morbidities such as anemia and thrombocytopenia13. Currently, after diagnosis most 
patients with leukemia undergo chemotherapy, radiation therapy, or stem cell 
transplants14. Leukemia tends to progress more quickly than lymphoma giving patients a 
slightly worse prognosis. The success rates for leukemia treatments show that 
approximately 61% of patients recover after treatment. The success rates are much less 
promising if the cancer recurs though. In addition, the 5-year survival rate for patients 
diagnosed with leukemia is only about 58% which is quite low compared to other cancers 
such as breast cancer (80%), thyroid cancer (95%), and prostate cancer (81%)15.  
1.2.2 B cell Lymphoma 
B cell lymphomas are cancers that are found in the lymph nodes or other lymphatic 
tissues when too many abnormal B cells are developed16. There are two classifications of 
lymphoma called Hodgkin’s lymphoma (HL) and Non-Hodgkin’s lymphoma (NHL). B 
cell Hodgkin’s lymphoma is characterized by abnormal large B cells called Hodgkin and 
Reed-Sternberg cells in the lymphatic system17. Non-Hodgkin’s B cell lymphoma is 
simply characterized by the abnormal growth of B cells that are not classified as Hodgkin 
and Reed-Sternberg cells in the lymphatic system18.  
When patients present with symptoms such as fatigue, weight loss, fever, or many other 
non-specific symptoms they may be tested for lymphoma. Lymphoma is most often 
diagnosed by taking a biopsy of the affected lymph node(s). There are approximately 9 
000 new diagnoses of lymphoma per year in Canada making it more common than 
leukemia. Lymphoma is staged according to the number of sites that it has reached. Stage 
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I lymphoma is only present in one lymphatic site, stage II is found in two or more sites 
above the diaphragm, stage III is found in sites below the diaphragm, and stage IV is 
found in organs outside of the lymphatic system. After diagnosis patients with lymphoma 
may undergo chemotherapy, radiation therapy, stem cell transplants, surgery, or be 
administered drugs that prevent additional growth of abnormal cells. Patients diagnosed 
with B cell lymphoma have a slightly better prognosis than patients diagnosed with 
leukemia due to the slower progression of the disease. In general, approximately 70% of 
patients with lymphoma recover after treatment and the 5-year survival for HL is 85% 
and NHL is 66%15. Unfortunately, like leukemia, if the cancer recurs the chance of 
survival is greatly diminished. Treatments that could allow even larger proportions of 
patients diagnosed with B cell malignancies to recover and improve the outcomes of 
patients that experience recurrence would be extremely valuable. For this reason, it is 
important to continue to study therapies for B cell malignancies so that we can further 
improve the treatment outcomes of these patient populations.  
1.3 T Cells  
 
T cells are another type of leukocyte or white blood cell that acts as a specialized immune 
cell in the body19. The immune system provides our body with protection from bacteria, 
viruses, fungi, and other toxins. T cells specifically respond to foreign antigens present in 
the body to protect against virus infected and transformed cells. T cells are made in the 
bone marrow and then differentiate into cytotoxic (CD8) or helper (CD4) T cells in the 
thymus, hence their name. Figure 1.1 illustrates the mechanisms of action that T cells 
take to kill infected cells in the body. CD4 T cells protect the body from infection by 
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releasing cytokines such as IFN-g, TNFa, IL-12, IL-4, IL-5, and IL-13 when they 
encounter antigens, which then activates other immune cells to orchestrate an immune 
response specific to the invader20. CD8 T cells directly bind to cancer cells or infected 
cells to kill them through the Fas/Fas ligand pathway or, more commonly, the 
perforin/granzyme pathway21. Briefly, the perforin/granzyme pathway is when activated 
cells secrete the membrane disrupting protein perforin and the serine proteases called 
granzymes by exocytosis causing apoptosis of the target cell22. The Fas/Fas ligand 
pathway occurs when the Fas ligates to FasL and starts a cascade that leads to cell 
apoptosis23. These cytotoxic functions only occur after the T cells have been activated 
which naturally occurs when two conditions are met. The first condition is that the T cell 
receptor (TCR) must bind to an antigen presented on a major histocompatibility complex 
(MHC) of an antigen presenting cell (APC). The second condition is that a CD28 
molecule on the T cell must bind to a CD80 or CD86 molecule on the APC, or in some 
cases CD8 T cells can be activated by co-stimulation with CD70 or CD137 (4-1BB)24. In 
addition, co-stimulatory receptors such as 4-1BB, OX40, and ICOS can ensure survival 
of the T cell as long as the T cell strongly recognizes the antigen on the APC. The ability 
of T cells to recognize and respond to transformed cells is crucial for humans to remain 
cancer free. Unfortunately, cancer cells can evade T cell responses by downregulating the 
MHC class 1 molecules, inhibiting apoptotic pathways, and inducing anergy in T cells 
which allows them to tolerate cancer cell presence25. Once this occurs, T cells cannot 
continue to recognize cancer cells and mount an effective cytotoxic response leading to 




Figure 1.1: Effector T cell killing mechanisms. (1) Perforin (PFN)/granzyme (GzmB) 
pathway. (2) Fas Ligand (FasL)/Fas receptor pathway. (3) Release of cytokines such 






1.3.1 T Cell Immunotherapies 
T cell immunotherapies are a relatively new class of cancer treatment that takes 
advantage of the natural cytotoxicity of T cells. T cells are removed from a patient and 
modified ex vivo to give them advantages over naturally occurring T cells in the body 
before they are adoptively transferred back into patients26. T cell therapies were first used 
to treat cancer patients in 1988 and since then many variations of T cell therapies have 
been developed and tested27. Most notably there is tumour infiltrating lymphocyte (TIL) 
therapy, cancer antigen-induced specific T cell therapy, and engineered TCR T cell 
therapy. TIL therapy was the first T cell therapy developed and tested in patients28, 29. 
They are produced by taking T cells from surgically resected tumours, isolating the TILs 
that show reactivity to cancer cells ex-vivo, and then expanding these TILs to produce a 
large population of tumour fighting T cells. This population of TILs is then re-infused 
into the patient to boost the T cell response against cancer cells. They have shown 
moderate responses in patients with melanoma with up to 50% response rates in patients 
when lymphodepleting chemotherapy was used, but only a 20% complete response rate 
was achieved30. Similarly, cancer antigen-induced specific T cells can be used to fight 
cancer by making a cancer specific population of T cells ex vivo for adoptive transfer31,32. 
Cancer antigen-induced specific T cells are made by isolating T cells from patient 
peripheral mononuclear blood cells (PBMCs) or from resected tumours and then 
activating them with antigen presenting cells that present cancer antigens specific to the 
patient’s tumour type. Like TILs, this therapy has shown some success in patients with 
metastatic melanoma33. The advantage of antigen-induced specific T cells over TILs is 
that they are easier to produce as patient T cells can be isolated from blood instead of a 
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tumour biopsy. Finally, engineered TCR T cell therapies are most often produced by 
isolating T cells from patient PBMCs, cloning an antigen specific TCR that was found in 
the patient’s PBMCs or TILs, engineering the T cells to express the cancer specific TCR 
using lentivirus or gamma retroviruses, and then expanding this population before re-
infusion34. The antigen specific TCR can also be produced by treating transgenic mice 
with cancer antigen. Clinical trials treating melanoma and colorectal cancer have shown 
some promise in the past with few reported toxicities35, 36. Unfortunately, the natural 
binding affinity of TCRs against cancer specific antigens is generally still low and there 
is the potential for severe side effects depending on the TCR chosen. Altogether, 
although there have been some successful outcomes using these T cell therapies in 
clinical trials, they are very time consuming to produce and tend to only elicit an effective 
response in a small portion of patients37. CAR-T cells were recently developed to 
overcome some of the main limitations of previous T cell therapies by using custom 
designed receptors to specifically target cancer antigens.  
1.4 Chimeric Antigen Receptor (CAR) T cells   
CARs were first proposed by Gross et al. in 198938. The goal of the CAR is to 
accomplish specific targeting and killing of cancer cells by allowing for MHC 
independent target recognition and activation of T cells. As mentioned above, T cells are 
usually activated by an APC and then recognize cancer cells by binding to an antigen 
presented on an MHC molecule39. This is often exploited by cancer cells as they can 
evade the immune system by downregulating their MHC-associated antigen presentation. 
In contrast, CAR-T cells recognize cancer cells independently of the MHC by directly 
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binding to a tumour associated antigen (TAA) that is specific to the CAR40. CARs are 
fusion proteins that mediate T cell activation using a recognition domain and T cell 
signaling domains independent of the TCR (Figure 1.2). This allows for more timely 
activation of T cells directly in the presence of cancer cells and fewer instances of tumour 
escape41. After activation, CAR-T cells can either directly kill cancer cells using the 
perforin and granzyme axis or the Fas and Fas ligand axis, or indirectly kill cancer cells 
by releasing cytokines that recruit other immune cells. Studies have shown that both CD4 
and CD8 CAR-T cells most often exhibit cytotoxicity through the perforin and granzyme 
pathway42. CD4 CAR-T cells express lower amounts of perforin and granzyme causing 
their cytotoxic response to be delayed compared to CD8 CAR-T cells. Despite their 
delayed target cell response, studies have shown that both subsets are important for 
proper target cell killing and that they kill equal amounts of tumour cells in vivo43. The 
ability of a CAR-T cell to persist in the body and continuously fight cancer is highly 




Figure 1.2: T cell and CAR-T cell activation and survival signaling. (a) T cells are 
activated by MHC interaction with the TCR (signal 1) and co-stimulation by CD80-
CD28 interaction (signal 2). (b) CAR-T cells are more easily activated as they only 








1.4.1 CAR Design 
Generally, CARs accomplish antigen specific activation using an extracellular domain, a 
transmembrane domain, and an intracellular signaling domain. The extracellular domain 
contains the antigen recognition domain that most often consists of a single chain 
variable fragment (scFv) derived from monoclonal antibodies to target a TAA. Recently a 
synthetic version of an antibody targeting domain has been developed that could be used 
in place of an scFv called designed ankyrin repeat proteins (DARPins)44. They may be 
advantageous because they are smaller, extremely stable, and can be used to make multi-
specific CARs which is a growing area of research. The transmembrane domain spans the 
cell membrane and is essential for transmission of the receptor-binding signal after the 
extracellular domain binds a TAA. Finally, the signaling domain is made up of a CD3-z 
subunit derived from the signaling domain in a TCR. It undergoes conformational 
changes when the CAR binds to a TAA allowing for downstream activation of the T 
cell45. The CAR signaling domain may also include the signaling endodomains of co-
stimulatory molecules to mimic the co-stimulation (signal 2) that occurs during APC 
dependent T cell activation.  
1.4.2 Generations of CAR-T cells 
There are five generations of CAR-T cells to date with each generation offering 
additional features than the generation before it. First-generation CARs only contain an 
scFv and CD3-z signaling domain. Their lack of co-stimulatory molecules, a hallmark 
part of T cell activation, caused them to have limited activation potential. Without proper 
activation, first generation CAR-T cells had limited cytotoxicity and persistence46. This 
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limitation led researchers to develop the next generation CARs. Second generation CARs 
were designed to include a co-stimulatory molecule in the intracellular signaling domain 
to improve their activation potential and persistence47. The most common co-stimulatory 
molecules used in CARs are 4-1BB and CD2848. The 4-1BB co-stimulatory molecule is 
better at promoting long-term persistence of CAR-T cells and stimulating memory T cell 
generation49. The CD28 co-stimulatory molecule is ideal for potent CAR-T cell 
cytotoxicity and IL-2 production. Third generation CARs were developed next in an 
attempt to further improve the signaling and survival of CAR-T cells. They contain two 
co-stimulatory domains such as OX40 and CD28 instead of just one costimulatory 
domain to enhance the survival of the CAR-T cells50. Current data is showing that 
including two co-stimulatory domains does not appear to increase the efficacy of the 
therapy compared to second generation CARs51. Fourth generation CAR-T cells, often 
called TRUCKS (T cells redirected for antigen‐unrestricted cytokine‐initiated killing), 
have been developed in an attempt to improve CAR-T cell efficacy against solid 
tumours52. Fourth generation CARs use the framework from second-generation CARs 
that contain only one co-stimulatory molecule. They combine the CAR response with a 
nuclear factor of activated T cells (NFAT) domain that releases cytokines such as IL-12 
to make CAR-T cells more resistant to the immunosuppressive tumour 
microenvironment53. Recently, fifth generation CARs were developed to try to further 
improve the survival of CAR-T cells. They use the framework of a second-generation 
CAR with the addition of a fragment of IL-2 receptor b (IL-2Rb) that can bind to 
STAT354. This domain is able to activate the JAK-STAT pathway which is important for 
preventing terminal differentiation of the T cells. Overall, there are still many studies 
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needed to fully understand the mechanisms of activation and cell death achieved by 
CAR-T cells, but their potential is undeniable based on clinical trials.   
 
1.4.3 CAR-T Cell Production 
 
CAR-T cell therapies are produced in current good manufacturing practice (cGMP) 
facilities that are equipped to ensure patients are receiving sterile and high-quality 
therapies55. Figure 1.3 illustrates the CAR-T cell manufacturing steps. Autologous T cells 
are most often used for CAR-T cell production to avoid graft versus host disease56. T cell 
collection begins with leukapheresis which is a process that removes leukocytes 
including T cells from the patient’s blood before returning the blood back to the patient57. 
Once T cells have been isolated, they are expanded by activating them through their T 
cell receptor (signal 1) and their co-stimulatory domain (signal 2). Multiple companies 
sell products for T cell activation such as CD3/CD28 antibody coated magnetic beads, 
antibody coated nanobeads, anti-CD3 antibodies, expamer technology, and antigen 
presenting cells. CD3/CD28 coupled magnetic beads called Dynabeads were used in this 
thesis as a convenient and easily removable method for T cell activation58. In addition, T 
cells are cultured in media supplemented with IL-2 to encourage proliferation. After 
activation, T cells are genetically modified to express a CAR specific to the patient’s 
cancer type. Stable CAR expression in T cells is most often accomplished using lentiviral 
or gamma retroviral vector transduction59. Gamma-retroviral vectors were the first 
method used to generate CD19 CAR-T cells for clinical use. Gamma-retroviruses are a 
valuable option for clinical CAR-T production because they are easier to produce, but 
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they can only transduce dividing cell populations and they pose a larger risk for 
insertional oncogenesis60. Currently, the most popular method for CAR transduction in 
clinical trials is lentiviral vectors61. Lentiviral transduction can be performed in any phase 
of the cell cycle and their gene integration occurs in safer locations compared to other 
viral transduction methods. After transduction, the engineered CAR-T cells need to be 
expanded to obtain large populations for adoptive transfer. For clinical manufacturing of 
CAR-T cells, billions of CAR-T cells are required which has led to the use of bioreactors 
that mimic ideal body conditions for cell growth62. Bioreactors are capable of 
consistently feeding the cells, removing waste, and rocking the cells back and forth to 
achieve gas transfer allowing for rapid expansion of CAR-T cells. After expansion, the 
CAR-T cells are used for treatment as long as they pass all of the safety, identity, and 
purity testing checkpoints during production63. The production and characterization of 





Figure 1.3: CAR-T cell production process. Blood is removed from a patient and 
then T cells are isolated from the blood. Next, T cells are engineered to express an 
antigen specific CAR and then expanded. After expansion, the CAR-T cells are 






1.4.4 CAR-T Cell Administration  
Patients are often treated with chemotherapy for lymphodepletion prior to CAR-T cell 
adoptive transfer64. Lymphodepletion is the destruction of lymphocytes including T cells, 
B cells, and NK cells in the body. It helps in adoptive cell transfer-based therapies by 
removing regulatory T cells, suppressing the patient’s immune system, and activating 
antigen presenting cells. Once lymphodepletion is performed, that patient is ready for 
their CAR-T cell infusion. The CAR-T cell dose that patients receive ranges from 1 × 104 
to 1 × 1010 cells/kg in clinical studies and they are most often administered intravenously 
(IV) in one dose using a slow infusion65, 66. Studies have also begun to test the efficacy of 
local or intratumoural (IT) injections of CAR-T cells or injecting the CAR-T cells in 
multiple slow infusions at different time points67, 68. Ideally, CAR-T cells should remain 
in the patient after injection until the cancer is eradicated69. Tests have shown that they 
can survive anywhere from 6 weeks to 5 years in patients, although more consistent 
follow ups with patients after treatment will continue to improve this data70-72.  
 
1.4.5 CAR-T Cell Therapy Outcomes 
There have been many TAA specific CAR-T cells studied to target a large variety of 
cancer types since the first development of CAR-T cells. The most notable CAR-T cell 
therapies to date are second generation CD19 targeting CAR T cells as they were the first 
to make it to large scale clinical trials in patients. They target the CD19 antigen that is 
found in low levels on normal B cells but is over expressed on B cell malignancies. CD19 
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is an ideal target because it is only expressed by B cells which means off-target cell 
killing during treatment will be contained to the B cell population73. Most clinical studies 
use different variations of CD19 CAR-T cells which has an effect on the outcome of the 
study. In general, CD19-CAR-T cells are showing a response rate (RR) of 72% in 
patients with B cell malignancies across all clinical trials which is especially impressive 
as these patients did not respond to or relapsed after traditional cancer treatments74. In 
particular, patients with B cell ALL have shown amazing results with complete remission 
(CR) rates of up to 93% in recent clinical trials75. Interestingly, comparisons between CR 
rates in a recent systematic review of CD19 CAR-T cell clinical trials treating ALL 
showed a difference between the treatment outcomes in patients treated with 4-1BB 
containing CARs (CR=86%) compared to CD28 containing CARs (CR=74%)76. In 
addition, diffuse large B-cell lymphoma (DLBCL), which is a form of NHL, has shown 
impressive CR rates of approximately 54% in patients with refractory disease using 
CD19 CAR-T cells77.  These trials resulted in Health Canada approval of two second 
generation CD19 CARs for the treatment of specific B cell malignancies. Kymriah 
(CTL019, Tisagenlecleucel) developed by Novartis was the first CAR approved by 
Health Canada in 2018 to treat children and young adults with B cell ALL who relapse or 
are not eligible for stem cell transplants. Yescarta (KTE-C19, Axicabtagen ciloleucel) 
developed by Kite/Gilead was approved next by Health Canada in 2019 to treat patients 
with relapsed or refractory DLBCL. These therapies differ slightly as Kymriah is 4-1BB 
driven and engineered using lentivirus and Yescarta is CD28 driven and engineered using 
retrovirus78, 79. Since their approval, developments have begun to create opportunities for 
the production and use of these therapies in Canada. In addition to CAR-T cells that 
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target B cell malignancies, there have also been minor successes in clinical trials using 
CAR-T cells that target solid tumours. For example, the use of GD2 targeting CAR-T 
cells to fight neuroblastoma in a recent clinical trial led to response rates of 
approximately 33%80. Overall, CAR-T cell therapies are still not showing very much 
efficacy against solid tumours with an average response rate among clinical trials of 9%.  
 
1.4.6 CAR-T Cell Limitations  
CAR-T cell therapies tend to cause a range of side effects during treatment. Studies have 
shown that over 85% of patients treated with CAR-T cells experience at least one adverse 
event77. One of the common side effects during treatment is cytokine release syndrome 
(CRS). CRS causes a range of symptoms that can be lethal in severe cases81. The 
symptoms of CRS include fever, hypotension, organ dysfunction, and increasing oxygen 
requirements of the body. The cause of CRS has been linked to high levels of cytokines 
such as interleukin-6 which may be elevated directly due to the anti-tumour response of 
CAR-T cells. Another common side effect after CAR-T cell transfer is tumour lysis 
syndrome82. Tumour lysis syndrome describes the metabolic complications that occur 
due to the breakdown of a large number of dying cells. Most often patients experience 
acute kidney failure, cardiac dysfunction, seizures, or nausea. Patients may also 
experience neurotoxicity during CAR-T cell treatment which also ranges in severity but 
tends to cause encephalopathy, seizures, delirium, agitation, and headaches83. In addition 
to the side effects caused by CAR-T cells, there are also direct cytotoxicities caused by 
CAR-T cells acting on healthy cell populations in patients84. On target/off tumour CAR-T 
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cell responses are extremely common as most TAAs are also expressed at lower levels on 
healthy cells in the human body. In the case of CD19 targeting CAR-T cells, CD19 is an 
excellent TAA because it is overexpressed on B cell malignancies, but it is also expressed 
on healthy B cells. Therefore, during treatment with CD19 CAR-T cells the patients will 
experience B cell aplasia85.   
Another limitation of CD19 CAR-T cells is that they do not mount an effective response 
in every patient. For example, there are still approximately 30% of patients with B cell 
malignancies that do not respond to CD19 CAR-T cell therapies. Even in successful 
cases, relapse still occurs in up to 50% of patients that responded to the therapy86. These 
sub-optimal CAR-T cell responses may be due to a lack of CAR-T cell expansion or 
persistence after injection, but there is limited patient specific data to support this87. 
Although these values are still much more encouraging than the response rates of CAR-T 
cells targeting solid tumours, further optimization of CD19 CAR-T cell therapies could 
continue to improve patient outcomes.  
 
1.4.7 CAR-T Cell Monitoring  
In order to effectively optimize current and emerging CAR-T cell therapies, accurate data 
on the fate of T cells needs to be available after injection. CAR-T cell monitoring is 
required to gain knowledge of CAR-T cell biodistribution and persistence in patients and 
learn how these characteristics correspond to treatment outcomes and side effects. 
Currently, blood tests are used to monitor CAR-T cell response after adoptive transfer 
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into patients88. These blood tests employ flow cytometry, polymerase chain reaction 
(PCR), or a combination of both to determine the persistence and expansion of CAR-T 
cells in the blood after injection. Blood tests are a relatively easy and cost-effective 
method for determining number of circulating T cells, but they cannot provide any real 
time information on the location of CAR-T cells in the body. This leads to a lack of data 
on the number of CAR-T cells that have made it to cancer locations compared to the 
number of CAR-T cells in off target locations. Minn et al. showed that the number of 
circulating CAR-T cells detected using blood tests did not correlate to the number of 
CAR-T cells that were present in tumours based on positron emission tomography (PET) 
images89. This suggests that the number of CAR-T cells detected in peripheral blood may 
not be a reliable method for predicting treatment response. In addition, blood tests are 
unable to predict neurotoxicity or CRS severity at this time due to limited access to IL-6 
testing and no current available markers for neurotoxicity90.   
Studies have begun to look at molecular imaging techniques to complement current 
clinical blood tests. The rationale is that they can provide patient specific information on 
the location(s) and persistence of CAR-T cells during treatment. PET is a widely used 
clinical imaging modality because of its high sensitivity and tissue penetration in 
patients91.   Sellmyer et al. used PET to track escherichia coli dihydrofolate reductase 
enzyme (eDHFR) expressing CAR-T cells in a mouse model of osteosarcoma after an 
infusion of [18F]-trimethoprim (TMP)92. They successfully detected the presence of CAR-
T cells in cancer locations in mice over time. They also noticed that they could detect 
CAR-T cells in the spleen at earlier timepoints before tumour invasion occurred. Minn et 
al. used PET to track prostate-specific membrane antigen (PSMA) expressing CAR-T 
22 
 
cells in a model of leukemia after an infusion of 18F-DCFPyL89. Early imaging time 
points showed expansion of CAR-T cells in the bone marrow and later images showed 
accumulation of CAR-T cells in the tumour proving that this imaging technique can 
monitor treatment progression over time. A clinical study has also been performed by 
Yaghoubi et al. to detect cytotoxic T lymphocytes (CTLs) that were labeled with herpes 
simplex virus 1 thymidine kinase (HSVtk1) using 18F-FHBG and PET in a patient with 
glioblastoma93. They were able to detect the intracranially injected CTLs 2 hours after an 
injection of 18F-FHBG. They found that the CTLs had localized in the location of a 
resected tumour as well as the new tumour that they were targeting. The images 
confirmed that their injection was effective and that the cells were able to migrate to 
tumour locations. Despite promising results with PET, there is often background uptake 
of the tracer in organs such as the stomach, thyroid, and kidneys which may mask the 
signal of CAR-T cells in these locations. In addition, longitudinal cell tracking studies are 
limited using PET due to radiation dose concerns for both the patients and the adoptively 
transferred cells94.   
MRI may be advantageous over PET for CAR-T cell tracking as scans are performed 
using non-ionizing radiation leading to fewer concerns when planning longitudinal cell 
tracking ventures. MRI also has excellent soft tissue differentiation and resolution 
compared to PET. Brewer et al. used MRI to track super paramagnetic iron oxide (SPIO) 
nanoparticle labeled CTLs in a mouse model of cervical cancer95. They were able to 
detect CTLs in the tumours 24 hours after injection and distinguish differences in the 
location of the CTLs based on whether or not the mouse was given a cancer vaccine prior 
to labeled CTL treatment. In addition, Lui et al. tracked T cells using MRI by labeling 
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them with nano-sized iron oxide nanoparticles prior to injection.  Their nanoparticle 
achieved an impressive labeling efficiency of over 90% in T cells and enabled the 
detection of the T cells in vivo96. Limitations of using iron oxides are that they cause 
hypointensities in images. Hypointense regions are not specific to iron labeled cells and, 
therefore, do not allow for quantification of adoptively transferred labeled cells. There 
have not been any clinical studies tracking T cells with MRI to date, but there is a lot of 
potential in this field as other therapeutic cell populations have been successfully tracked 
using cellular MRI97-99. One of the most recent promising methods for tracking CAR-T 
cells in clinical settings is fluorine-19 (19F) MRI which combines the anatomical 
information of 1H MRI with the detailed “hotspot” imaging of 19F MRI.  
1.5 Magnetic Resonance Imaging 
MRI provides excellent soft tissue contrast allowing for the generation of highly detailed 
anatomical images. MRI was successfully used to image human anatomy for the first 
time in 1977 based on the principles of nuclear magnetic resonance (NMR)100. NMR 
relies on the principle that nuclei in the presence of a magnetic field can absorb energy 
from radiofrequency (RF) pulses that are generated at frequencies specific to the nuclei of 
interest called the larmor frequency101. The absorbed energy is then dissipated to form 
signal when the RF pulse is turned off. This detected signal can then be used to determine 
the number of nuclei present in a sample as long as the properties of the sample such as 
relaxation and chemical shift are known. MRI most commonly relies on the excitation of 
protons (1H) to form signal102. 1H are the most widely used nuclei for MRI because they 
make up a large portion of the human body and they have a high gyromagnetic ratio of 
42.58 MHz/T. The three main components of an MR scanner are the magnet, the gradient 
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coils, and the RF coil. Each of these parts work together to manipulate nuclei and in turn 
obtain signal.  
 
Many nuclei such as 1H naturally possess a quantum mechanical property called “spin” 
(Figure 1.4A)103. These nuclei have a net magnetization vector (M) which is the sum of 
all of the magnetic moments of each nuclei in a given region. When nuclei are not in a 
magnetic field, they have a net magnetization vector of zero because the individual 
magnetic moments are randomly oriented104. The magnet which can range between 
clinical field strengths of 1.5-3 Tesla (T) or pre-clinical field strengths of 7-11.7T creates 
a magnetic field that causes the nuclei to obtain a small non-zero net magnetization. Once 
the majority of the nuclei align with the main magnetic field in the scanner, a RF pulse 
can be applied to excite the nuclei, changing the orientation of the net magnetization 
vector (Figure 1.4B)105. This net magnetization vector then relaxes back to equilibrium 
via transverse relaxation and longitudinal relaxation which generates detectable signal 
when the RF pulse is turned off (Figure 1.4C). Transverse relaxation is described by T2 
which is the transverse relaxation time constant or spin-spin relaxation time constant. T2 
relaxation describes the dephasing of spins caused by energy transfer between 
neighbouring nuclei resulting in the decay of transverse magnetization. The transverse 
magnetization decays exponentially with time as a result of the properties of tissues. The 
longitudinal relaxation of the nuclei is described by T1 which is the longitudinal 
relaxation constant or spin-lattice constant. Longitudinal magnetization recovers back to 
equilibrium independently of the transverse magnetization. T1 relaxation describes the 











Figure 1.4: Nuclear precession and T1 and T2 Relaxation. (a) The behaviour of a proton 
placed in a magnetic field (B0) where w0 is the Larmor frequency. (b) An RF pulse causes 
excitation of the protons. When the RF pulse is removed, the protons relax through T1 





1.5.1 Image Contrast 
1H nuclei in different tissues relax at different rates which can be taken advantage of to 
create contrast in MR images107. Contrast in MR images can be weighted depending on 
proton density (PD), T1 relaxation time, or T2 relaxation time. PD weighted images have 
higher signal in areas that are proton dense. T1 weighted images have higher signal in 
regions with shorter T1 relaxation such as fat and lower signal in areas with longer T1 
relaxation times such as water. T2 weighted images have higher signal in areas with a 
longer T2 relaxation time such as fluid and lower signal in areas with shorter T2 
relaxation times such as fat. Many tumours for example appear darker in T1 weighted 
images and brighter in T2 weighted images.  
1.5.2 Magnetic Field Gradients 
Magnetic field gradients are essential for MRI because they allow for spatial localization 
and encoding of information108. Gradient coils are independently pulsed to create small, 
localized field gradients that can be used in conjunction with RF pulses to target the 
excitation of spins to certain locations. To form an image, an anatomical slice is excited 
in a plane of interest and then information encoding is applied along the other two 
directions using frequency and phase encoding gradients. Generally, the plane of interest 
is along the z direction, the phase encoding is along the y direction, and the frequency 
encoding is along the x direction. Frequency encoding gradients change the larmor 
frequency of the nuclei in a gradient along the x direction to elicit a signal that is based 
on the location of the nuclei along the slice. Phase encoding gradients are turned on 
independently of the frequency encoding gradients to change the larmor frequency in the 
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y direction to provide additional information on the location of the nuclei based on their 
phase. When RF pulses are turned off, all of this information is collected by 
radiofrequency coils to create MR images.  
1.5.3 Radiofrequency Coils  
RF coils are responsible for the excitation and subsequent detection of energy from the 
nuclei109. The two main RF coils are surface coils and volume coils110. Volume coils are 
more commonly used because of their ability to obtain uniform signal that does not 
depend on depth. In cases where deep tissues are being probed such as the head or knee it 
is especially important to use a volume coil. Surface coils have higher sensitivity but 
there is signal drop off as the distance between the coil and tissue is increased. Surface 
coils are most often used for imaging superficial anatomy such as the spine or 
temporomandibular joint. In this thesis, a surface coil was used as our imaging was 
focused on subcutaneous tumours so signal drop off with imaging depth was not of 
concern. In addition, the coil we used is dual tuned to enable 1H MRI and fluorine-19 
(19F) MRI so it was important to maximize signal.  
1.5.4 Pulse Sequences  
Pulse sequences are a set of instructions for the RF coil and gradients to follow to 
generate specific MR images. The main characteristics of a pulse sequence are time to 
echo (TE), repetition time (TR), and flip angle (FA). Generally, TR is the time between 
the start of an RF pulse and the start of the next RF pulse applied to the same slice, TE is 
the time between the start of an RF pulse and the peak of the echo detected, and FA is the 
angle of the pulse applied to flip the net magnetization vector. Spin echo (SE) and 
gradient echo (GE) sequences are the most common pulse sequences. SE sequences are 
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generally used to create T2 weighted images111. They are insensitive to magnetic field 
inhomogeneity, which is useful for avoiding image artifacts, but the image acquisition 
takes longer. GE sequences are faster because they have shorter TR, but they are more 
sensitive to susceptibility artifacts. The sequence that our lab is most interested in is a GE 
sequence called balanced steady state free precession (bSSFP). It is also referred to as 
TrueFISP, FIESTA, or balanced FFE depending on the manufacturer of the MRI. The 
bSSFP sequence begins with a fast train of pulse sequences that do not allow time for the 
transverse relaxation to decay and thus, a steady state of magnetization is reached112. This 
allows for high signal to noise ratio and fast image acquisition. bSSFP provides mixed 
T2/T1 contrast images which limits some of the diagnostic uses of the sequence but still 
provides useful anatomical images. Once the MRI protocol is completed, all of the 
information that was collected into the MR system processor is automatically processed 
using fourier transforms for image reconstruction. Post processing tools such as Horos or 
Osirix can then be used to analyze image characteristics. 
 
1.6  19F Magnetic Resonance Imaging 
 
In addition to protons, there are other nuclei that can be used for MRI such as 19F, 
Carbon-13, Sodium-23, and Phosphorus-31. Of these additional nuclei, 19F is considered 
one of the best candidates for MRI because it has a gyromagnetic ratio of 40.08 MHz/T 
and a sensitivity of 83% when compared to protons113. In addition, there are only trace 
amounts of 19F in the bones and teeth of humans which is below the detection limits of 
MRI allowing for background free “hotspot” imaging of 19F. The “hotspot” data can then 
be overlayed onto 1H images to provide anatomical context114. 19F MRI was successfully 
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developed by Holland et al. in 1977 and since then has become a popular imaging 
modality for cell tracking115. It has been used by multiple groups to provide valuable 
information on adoptively transferred labeled cell populations116. 19F cellular MRI has the 
advantage of specific, background free detection of 19F labeled cells. The “hot spot” 
characteristic of 19F MRI is highly valuable when compared to other MRI contrast agents 
including iron oxide nanoparticles that indirectly cause negative contrast in MR images 
or manganese and gadolinium that indirectly cause positive contrast in MR images. 
Although the sensitivity of 19F MRI is relatively low compared to other imaging methods, 
it can still be used to detect thousands of labeled cells117. 19F MRI was proven to be 
valuable for clinical cell tracking ventures when Ahrens et al. used it to detect 
perfluorocarbon (PFC) labeled dendritic cells in patients118.   
19F MRI is performed on standard MR scanners using an RF pulse specific to the 
resonant frequency of 19F nuclei119. Specialized RF coils have been designed that can 
perform dual 1H and 19F MRI by emitting and receiving at both frequencies. Since 19F 
MRI directly detects the spin density of 19F nuclei, the contrast in 19F images is based on 
the density of 19F nuclei per voxel in the body. The linear relationship between 19F 
content in a voxel and 19F signal and the lack of endogenous 19F signal in the body allows 
19F MRI to be quantitative120. The number of 19F spins in a given region of interest can be 
calculated using the signal obtained from reference tubes containing a known amount of 
19F. If cells are labeled ex vivo prior to adoptive transfer, there is also the potential to 
calculate cell number based on the 19F images. Calculating cell number requires three 
pieces of information: 1) The number of 19F spins per cell prior to injection as determined 
by 19F NMR, 2) the signal obtained from the region of interest containing the 19F labeled 
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cells in the MR image, 3) the signal obtained from the reference tubes with known 19F 
content121. One major limitation to the cell number quantification is that dividing cell 
populations will not be accurately quantified over time.  
1.6.1 Cell Labeling for 19F MRI 
PFCs are tracer agents with a strong C-F bond making them stable at physiological pH 
and non-toxic in humans122. They have historically been used in the clinic as blood 
substitutes because of their ability to dissolve oxygen. They have also been co-opted by 
imaging scientists as a cell label to enable cell detection with 19F MRI. 
Perfluorooctylbromide (PFOB) was one of the first PFCs that was used extensively in 
patients as a blood substitute and in clinical trials for inflammation and bowel imaging123. 
Unfortunately, PFOBs showed 8 peaks in an NMR spectrum making SNR and image 
quality worse. This led to the development and use of Perfluoropolyethers (PCPEs). 
PCPEs have one main peak on a 19F NMR spectrum and they have high fluorine 
content124. The ideal PFC tracer for clinical cell tracking would be commercially 
available and extensively studied. While there are many different possible formulations 
for 19F PCPEs, this thesis focuses on the chemically modified PCPEs made by CelSense 
as they are commercially available and well-studied for in vivo cell tracking applications. 
CelSense 19F PFC emulsions have high fluorine content to enable 19F MRI and are 
available with fluorescence probes to enable detection with flow cytometry or 
histochemistry. They also have a small diameter of 165nm and a slightly negative charge 
to enable cell uptake by endocytosis125. They have been FDA approved in the United 
States and used in clinical trials in patients126. They show very low toxicity in patients 
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and no significant toxicities in many cell lines. Cell labeling is accomplished by simple 
co-incubation of the PFCs and the cell of interest. After labeling, PFCs stay in a labeled 
cell as long as the cell remains viable and is divided between daughter cells upon cell 
division. When a labeled cell dies the label is released and quickly cleared by the 
reticuloendothelial system (RES) to the liver where they will slowly be released into the 
blood and exhaled127. There is also a chance that they may be taken up by phagocytic 
bystander cells such as macrophages. Recently, Helfer et al. showed that labeling T cells 
with 19F PFCs is possible at a large clinical scale without harming the final product128.   
 
1.6.2 CAR-T Cell Imaging with 19F MRI  
 
19F MRI has been used to detect the location and number of many immune cell types to 
date129-131. In the past 5 years, CAR-T cells have been successfully labeled with 19F PFCs 
and detected using 19F MRI in vivo. Below is a summary of recent advances in imaging 
CAR-T cells using 19F MRI.  
In 2017, Chapelin et al. were the first to PFC label CAR-T cells and confirm intracellular 
localization of the PFC132. After successfully labeling the CAR-T cells without any 
negative effects on the CAR-T cell phenotype, they injected them into a mouse model of 
glioblastoma. The study showed that PFC+ CAR-T cells slow down the progression of 
cancer in their model compared to mice that received untransduced T cells or no 
treatment. They were also able to detect the presence of PFC labeled CAR-T cells in 
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tissue samples of the liver, lungs, tail, spleen, lymph nodes, thymus, tumours, and 
kidneys of treated mice up to 14 days post injection using ex vivo NMR. 
 Hingorani et al. used trans-activator of transcription (TAT) conjugated PFC 
nanoemulsions to label and track CAR-T cells in a mouse model of glioma133. They 
imaged the cells 24 hours after an intratumoural injection using an 11.7T scanner and 
found that they could detect almost 100% of the injected cells. This study was the first to 
show detection of PFC+ CAR-T cells with 19F MRI.  
Very recently, Chapelin et al. imaged PFC+ CAR-T cells over time in a mouse model of 
glioblastoma using an 11.7T MRI134. They were able to show for the first time that 
intratumourally injected CAR-T cells could be detected in tumour sites using 19F MRI up 
to day 10 post-treatment using an 11.7T scanner. They also looked at the intracellular 
partial pressure dynamics of CAR-T cells using 19F MRI.   
Each of these studies made important progress in CAR-T cell tracking using 19F MRI.  
The main limitation for clinical translation of these studies is that they used field 
strengths well above clinical standards to improve signal detection. The sensitivity is 
improved at higher field strengths allowing for shorter scan times and fewer cells to be 
detected. This thesis is focused on imaging PFC+ CAR-T cells using clinical 3 T MRI 
and a human surface coil. By using clinical field strengths, we continue to gain valuable 
information on this imaging technique that will improve the chances of clinical 




1.7 Bioluminescence Imaging 
Bioluminescence imaging (BLI) is a valuable pre-clinical imaging technique to track 
proliferating cells over time in vivo. BLI reporter genes are stably expressed in cell 
populations so that they are passed down to daughter cells during cell division which 
allows them to be continually detected. BLI has been adapted by many researchers due to 
its low cost, high sensitivity, and high specificity135. The BLI system is composed of a 
black box imaging chamber with a heated stage where the subject is placed during 
imaging and a cooled charged couple device (CCD) camera that collects the emitted light 
from the subject. The system first acquires a photographic image for reference and then 
overlays the detected BLI signal onto the photograph136. Imaging time can be 
automatically determined by the BLI software and usually ranges from seconds to 
minutes depending on the amount of signal coming from the subject. Tracking cells is of 
particular interest using BLI because the characteristics of signal generation cause only 
viable engineered cells to be detected. This is a characteristic of the enzymatic reaction 
that takes place between the engineered cells and the injected substrate. For cell tracking 
purposes, cells are engineered to stably express luciferase genes prior to injection into the 
animal model. Bioluminescence images are then acquired by first administering the 
substrate to the subject to produce signal from the engineered cells. Mice are then imaged 
for up to 30 minutes after substrate administration until the peak signal is obtained. For 
analysis, regions of interest (ROI) can be manually placed onto the images displayed in 
the LivingImage software to assess the signal in the region. Longitudinal images can then 
be assessed to determine the relative number of viable engineered cells over time and 
their location(s). This is especially valuable when studying cancer therapies in pre-
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clinical models to determine if the relative number of viable cancer cells is decreasing 
after treatment.  
 
1.7.1 Genome engineering  
For cell tracking studies, cells of interest are cultured ex vivo and engineered to stably 
express a luciferase gene. Many luciferase enzymes have been isolated from different 
species and made available for imaging purposes137. Renilla luciferase and firefly 
luciferase (FLuc) are the most common transgenes for BLI. This thesis focuses on FLuc 
as it has a more favourable injection route and has better light penetration through tissues 
because its emission spectrum is more red shifted. When expressed, FLuc produces an 
enzyme that reacts with the substate D-luciferin in the presence of oxygen and adenosine 
triphosphate (ATP) to produce light138 (Figure 1.5). To accomplish stable gene 
expression, cell populations need to be engineered prior to their injection. In the past, my 
colleagues and I successfully used clustered regularly interspaced short palindromic 
repeats and crispr associated protein 9 (CRISPR/Cas9) to integrate FLuc into a safe 
harbour site in cells139. The greatest advantage of CRISPR/cas9 genome editing is that 
gene integration is site specific which means safe sites can be targeted to avoid 
behavioural modifications caused by insertional mutagenesis. Unfortunately, this process 
is still fairly inefficient compared to largely used methods such as lentivirus and 
gammaretrovirus transduction. Our lab and others have used lentivirus extensively to 
make stable cell lines because it is cost-effective, efficient, and relatively safe. In this 
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thesis we used lentivirus to produce FLuc expressing leukemia cells to enable the 

















Figure 1.5: Bioluminescence Imaging (BLI) diagram depicting the reaction between 
viable firefly luciferase expressing cancer cells and the substrate D-luciferin in the 
presence of oxygen and ATP to produce light, AMP, carbon dioxide, and 
oxyluciferin. The light is detected by the CCD camera to create an image. 
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1.7.2 Cancer Cell Imaging with BLI  
Cancer researchers rely heavily on methods that measure tumour burden when studying 
new therapies. Caliper measurement is a commonly used metric for measuring tumour 
volumes and is often used to determine the response of tumours to a new therapy140, 141. 
Although this method is easy to implement and very cost effective, tumour necrosis can 
occur much before a tumour changes in size. Therefore, if researchers are relying solely 
on changes in size to evaluate a response to treatment it might prolong the study and 
provide inaccurate estimates of how long it takes for the treatment to begin working. In 
contrast, BLI is an ideal method for cancer detection in pre-clinical models because it is 
cost-effective, specific to engineered cell populations, and only detects viable cells. BLI 
is an extremely valuable imaging method for studying cancer cell growth and subsequent 
treatment with therapies as signal is only produced by viable luciferase expressing 
cells142. Cancer cell growth can be monitored prior to treatment to determine a baseline 
for cancer signal. Downstream BLI post-treatment can then be used to monitor for cancer 
cell death as there will be less signal if cancer cells die. Therefore, as necrosis occurs 
tumour signal will decrease even if the volume does not change. Below are examples of 
studies that have successfully used BLI to detect cancer cell viability and growth over 
time in the presence of therapeutic cells.  
Rehemtulla et al. used BLI as a method to assess the cancer treatment response to 
chemotherapy142. They successfully imaged FLuc expressing glioma growth over time in 
rats using BLI to detect differences in signal before and after treatment. Their data 
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suggests that BLI may be a better measure of tumour burden over time compared to MRI 
tumour volume measurements because BLI only measures metabolically active cells.  
Parkins et al. used dual BLI to track RLuc expressing circulating tumour cells (CTC) that 
were engineered to express a suicide gene and then adoptively transferred into mice 
bearing FLuc expressing breast cancer143. We were able to compare the locations of the 
therapeutic cells and the cancer cells over time. In addition, we could determine the CTC 
treatment effect by comparing the BLI signal measurements over time.  
Finally, two of the previously discussed studies that imaged PFC+ CAR-T cells used BLI 
to evaluate the tumour response after treatment in combination with 19F MRI to evaluate 
the CAR-T cell location132, 134. They found that PFC+ CAR-T cells cause significant 
cancer cell death in mouse models of glioblastoma. Currently, no groups have looked at 
the difference in treatment response between PFC+ CAR-T cells and unlabeled CAR-T 
cells in vivo using BLI. This thesis focuses on determining if PFC+ CAR-T cells show 
the same treatment effect in vivo as unlabeled CAR-T cells using BLI.  
1.8 Acute Lymphoblastic leukemia Mouse Model  
There are many models developed to study human leukemia treatments in mice. In this 
thesis, we used NOD- Prkdcscid-II2rgtm1Wjl (NSG) mice because of their ability tolerate 
injections of human cells144. NSG mice are genetically modified to be immunodeficient 
in mature T cells, B cells, and nature killer cells. In addition, they lack other signaling 
pathways that are important for proper immune system functioning145. Specifically, the 
NOD mutation causes abnormal dendritic cell and macrophage function and removes the 
39 
 
complement system that is important for innate immunity. Generally, innate immunity is 
the first line of defense against pathogens that enter your body. The Prkdcscid severe 
combined immunodeficiency (SCID) mutation disrupts the development of mature T and 
B cells which comprise the adaptive immune response. The adaptive immune response is 
responsible for fighting viral, bacterial, and fungal infections in the body and is required 
for memory of infections which helps improve future immune function in the body. The 
II2rgtm1Wjl mutation removes functioning interleukin 2 receptor gamma which causes 
natural killer (NK) cells to be unable to differentiate and mount a proper immune 
response. NK cells recognize infected cells in the body by their lack of MHC I molecule 
and kill them to ensure that virally infected cells and early cancer cells do not persist. 
They have been shown to assist in the rejection of transplanted tissues, so it is very 
important that their function is blocked to allow for human cells to be injected into mice 
while avoiding severe side effects such as graft versus host disease and rejection146.  
Altogether, these mutations allowed us to implant the NALM6 cell line into mice to form 
acute lymphoblastic leukemia bearing mice. NALM6 cells are a human precursor B Cell 
leukemia cell line that originated from a 19-year-old man with ALL. NALM6 cells have 
been used by many researchers to study leukemia both in vitro and in mouse models147-
149. By implanting the NALM6 cells with Matrigel we were able to form solid 
subcutaneous tumours in the left hind flank of mice. This technique is ideal as it allows 
researchers to study human cancer in a model that can be easily injected with therapeutic 
cells and imaged89. Flank tumours were also ideal to minimize the effects of breathing 





1.9 Purpose of thesis  
This thesis uses 19F-based cellular MRI techniques to detect CAR-T cells in a murine 
model of B cell leukemia. The objectives of this work were to determine if PFC+ 
CAR-T cells could be detected using a 3 T clinical MRI scanner and to evaluate the 
performance of PFC+ CAR-T cells compared to unlabeled CAR-T cells using BLI. 
Our hypotheses are: 1) 19F based MRI performed on a 3T clinical system will be able 
to detect PFC labeled CAR-T cells in a mouse model of leukemia, and 2) PFC+ 
CAR-T cell cytotoxicity will not be significantly different from unlabeled CAR-T cell 
cytotoxicity in vivo. Chapter 2 demonstrates the application of 19F MRI to detect PFC 
labeled CAR-T cells in a mouse model of leukemia.  
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2 Visualizing CAR-T Cell Immunotherapy Using 3 Tesla 
Fluorine-19 MRI 
Purpose: Chimeric antigen receptor (CAR) T cell cancer immunotherapies have shown 
remarkable results in patients with hematological malignancies and represent the first 
approved genetically modified cellular therapies. However, not all blood cancer patients 
respond favourably, serious side effects have been reported, and the treatment of solid 
tumours have been a challenge. An imaging tool for visualizing the variety of CAR-T cell 
products in use and being explored could provide important patient-specific data on 
CAR-T cell location to inform on potential success or failure of treatment as well as off-
target toxicities. Fluorine-19 (19F) magnetic resonance imaging (MRI) allows for the non-
invasive detection of 19F perfluorocarbon (PFC) labeled cells. Our objective was to 
visualize PFC labeled (PFC+) CAR-T cells in a mouse model of leukemia using clinical 
field-strength (3 Tesla) 19F MRI and compare the cytotoxicity of PFC+ versus unlabeled 
CAR-T cells.  
Procedures: NSG mice (n=17) received subcutaneous injections of CD19+ human B cell 
leukemia cells (NALM6) expressing firefly luciferase in their left hind flank (1x106). 
Twenty-one days later, each mouse received an intratumoural injection of 10x106 PFC+ 
CD19-targeted CAR-T cells (n=6), unlabeled CD19-targeted CAR-T cells (n=3), PFC+ 
untransduced T cells (n=5), or an equivalent volume of saline (n=3). 19F MRI was 
performed on mice treated with PFC+ CAR-T cells days 1, 3, and 7 post-treatment. 
Bioluminescence imaging (BLI) was performed on all mice days -1, 5, 10, and 14 post 
treatment to monitor tumour response.   
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Results: PFC+ CAR-T cells were successfully detected in tumours using 19F MRI on 
days 1, 3, and 7 post-injection. In vivo BLI data revealed that mice treated with PFC+ or 
PFC- CAR-T cells had significantly lower tumour burden by day 14 compared to control 
cohorts (p<0.05). Importantly, mice treated with PFC+ CAR-T cells showed equivalent 
cytotoxicity compared to mice receiving PFC- CAR-T cells.  
Conclusions: Our studies demonstrate that clinical field-strength 19F MRI can be used to 
visualize PFC+ CAR-T cells for up to 7 days post intratumoral injection. Importantly, 
PFC labeling did not significantly affect in vivo CAR-T cell cytotoxicity. These imaging 
tools may have broad applications for tracking emerging CAR-T cell therapies in 
preclinical models and may eventually be useful for the detection of CAR-T cells in 
patients where localized injection of CAR-T cells is being pursued. 
 
2.1 Introduction 
Cancer is a devastating disease with over 220 000 Canadians receiving a cancer diagnosis 
each year [1]. Despite enormous effort, cancer continues to be one of the leading causes 
of death in the world [2]. There continues to be an urgent need to develop new cancer 
therapies that allow for a greater number of cancer patients to survive for significantly 
greater lengths of time after their diagnosis. Chimeric antigen receptor (CAR) T cell 
therapy was first proposed in 1989 and is now the first genetically modified cellular 
therapies to be approved for the treatment of B cell leukemia and lymphoma [3]. CAR-T 
cells are produced using a patient’s own T cells that have been isolated and engineered to 
express a cancer antigen-specific CAR [4]. The CAR redirects the T cells to bind and kill 
59 
 
the patient's cancer cells after injection. Multiple CD19-targeted CAR-T cell therapies 
have been approved in Canada after showing remarkable results in patients with B cell 
malignancies, providing a transformative, potentially curative therapeutic option [5]. 
Despite the success that CAR-T cells show against B cell malignancies, major challenges 
remain. Up to 30% of blood cancer patients do not respond to these therapies, many 
patients can relapse, and patients can also suffer from life-threatening side effects such as 
cytokine release syndrome or neurotoxicity [6]. In addition, CAR-T cells continue to 
show disappointing results against solid tumours [7]. Many of the disparate outcomes 
among patients receiving this therapy are thought to be due to CAR-T cells not 
proliferating and persisting in the body, proliferating and activating excessively, or 
homing to normal organs such as the brain [8]. However, due to the inadequate 
information provided by serial blood tests currently used by clinicians, we have limited 
evidence about the behaviour of CAR-T cells over time in individual patients. Therefore, 
methods to track the fate of adoptively transferred T cells would be extremely valuable 
for both pre-clinical and clinical studies to learn about the behaviour of CAR-T cells after 
injection. 
Cellular imaging is a potential complementary technology to blood tests involving non-
invasive imaging of cells labeled with imaging technologies to achieve information on 
cell fate after adoptive transfer. Ex-vivo labeling is a particularly invaluable approach for 
CAR-T cell therapies as they require ex-vivo processing for production regardless of 
whether or not imaging is implemented. The breadth of cellular imaging technologies 
available spans from preclinical imaging modalities such as fluorescence and 
bioluminescence imaging (BLI) to clinical modalities such as magnetic resonance 
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imaging (MRI), photoacoustic tomography, and positron emission tomography (PET) [9]. 
Importantly, successful PET imaging of intracranially infused cytotoxic T cells co-
expressing a PET reporter gene was demonstrated in glioma patients [10], [11].  
MRI is also being explored extensively as a clinical cell tracking tool. MRI provides 
images with fine spatial resolution and high soft tissue differentiation, uses non-ionizing 
radiation that can be beneficial for longitudinal studies, numerous MRI probes and 
reporter genes have been developed for ex vivo cell labeling, and MRI is broadly 
available within the healthcare system in most developed countries. Currently, most 
immune cell tracking studies utilizing MRI have been accomplished by labeling cells 
with iron oxide nanoparticles (IONS) [12]. Clinical imaging of ION labeled dendritic 
cells in melanoma patients was achieved by De Vries et al in 2005 [13]. IONs allow 
labeled cells to be detected with high sensitivity, even single cells in preclinical models, 
but detection of the cells can be difficult in locations such as the lungs as IONs cause 
hypointensities in images [14]. In contrast, fluorine-19 perfluorocarbons (PFC) are a 
tracer agent that is easily taken up by cells and can be detected directly by fluorine-19 
(19F) MRI [15]. 19F MRI cell tracking provides positive contrast which enables improved 
quantitation in comparison to ION imaging and has high specificity because there is no 
detectable endogenous 19F in the body. This technique is clinically relevant as PFCs were 
used off label in patients for many years as a blood substitute [16]. In addition, 19F MRI 
has been successfully used in the clinic to detect PFC labeled (PFC+) dendritic cells in 
patients [17]. Previous preclinical studies have shown the feasibility of labeling CAR-T 
cells with PFC and detecting them with high field-strength 19F MRI [18]-[20]. However, 
data supporting the ability to image PFC+ CAR-T cells using a clinical field-strength 
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scanner is lacking, which is important to demonstrate when assessing if translation of this 
technology into patients is feasible. Moreover, in vivo data comparing the cytotoxicity 
against tumors of CAR-T cells versus PFC+ CAR-T cells is lacking. 
In this study we focused on using 19F PFC based imaging to monitor CAR-T cells over 
time using clinical field-strength 3 Tesla MRI. In addition, we used bioluminescence 
imaging (BLI) to evaluate whether labeling CAR-T cells with PFC affects their in vivo 
cytotoxicity towards cancer cells. Our results indicate that this technique can reliably 
detect PFC+ CAR-T cells post-intratumoural injection using clinical field strengths. We 
also show for the first time that PFC labeling does not significantly affect in vivo CAR-T 
cell cytotoxicity in a mouse model of leukemia, which is important for potential future 
use of this imaging technique in patients.  
2.2 Materials and Methods 
2.2.1 Cancer Cells and Engineering 
A CD19 positive B cell acute lymphoblastic leukemia cell line (NALM6 cells; 
Cedarlane) was utilized for this study. NALM6 cells were maintained in RPMI medium 
supplemented with 10% fetal bovine serum (Wisent) and 1% antibiotic-antimycotic 
(100X; Thermofisher). NALM6 cells were engineered to stably co-express the 
fluorescence reporter tdTomato (tdT) and a codon-optimized bioluminescence firefly 
luciferase reporter (Luc2) using a lentiviral vector previously constructed in our lab [21]. 
Cells were transduced with lentiviral vector using polybrene (1.6ug/ml, Sigma Aldrich). 
Transduced cells were analyzed and sorted using fluorescence activated cell sorting 
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(FACSAria III flow cytometric cell sorter, BD Biosciences), and expanded prior to 
downstream use.  
2.2.2 Human T Cells and Engineering 
Frozen PBMCs from various donors were purchased from StemCell. PBMCs cells were 
cultured in ImmunoCult-XF T cell expansion medium (StemCell) supplemented with 
100U/mL interleukin-2 (Chiron) and 2µL (55µM) 2-mercaptoethanol (Sigma). T cell 
populations were obtained by thawing human PBMCs (StemCell) and activating 1x105 
cells per well with 2µL of 4x107 beads/mL Human T-activator CD3/CD28 Dynabeads 
(Thermofisher) as outlined in the protocol from Hammill et al. [22]. Twenty-four hours 
later, T cells were engineered to co-express a CD19 targeted CAR and green fluorescent 
protein (GFP) using a CD19 CAR-GFP lentiviral transfer plasmid expressing a second 
generation CD19 targeting CAR containing the 4-1BB co-stimulatory molecule 
generously gifted by Drs. Robert Holt and Brad Nelson (University of British Columbia) 
using an MOI of 5. Transduced and untransduced T cell populations were then expanded 
and evaluated with flow cytometry to evaluate CAR/GFP, CD3, CD4, and CD8 
expression. To produce PFC labeled (PFC+) CAR-T cells or PFC+ untransduced T cells 
for 19F MRI, T cell populations were labeled overnight with 5mg/ml Texas Red 
fluorescent dye conjugated PFC (CS-ATM DM Red, CelSense) and washed three times 




2.2.3 In Vitro Imaging 
To evaluate the minimum number of PFC+ CAR-T cells that could be detected at 3T, 
triplicates of CAR-T cell pellets containing decreasing numbers of labeled cells (2, 1, 0.5, 
0.25, 0.1 (x 106) cells) were imaged using 19F MRI. Samples were made by mixing 
labeled and unlabeled CAR-T cells to obtain a total of 2x106 cells per Eppendorf tube, the 
Eppendorf tube was then spun down to form pellets, and then topped with 1% agarose 
prior to MRI. The resulting samples were imaged at 3T using a clinical GE 3T MR750 
system following the same imaging protocols used for in vivo imaging (see below). 
Analysis of all 19F MRI images is described further below. 
To compare the cytotoxicity of PFC+ and unlabeled CAR-T cells, 5x104 NALM6-tdT-
FLuc cells were seeded with PFC+ or unlabeled CAR-T cells at increasing effector to 
target ratios (1:4, 1:2, 1:1). Twenty-four hours later, 1µL of D-luciferin was added to 
each well (30 mg/mL, Syd Labs) and BLI was performed immediately on an IVIS 
Lumina XRMS scanner (IVIS Lumina XRMS In Vivo Imaging System, PerkinElmer). 
BLI signal was evaluated with region-of-interest (ROI) analysis using LivingImage 
Software (Perkin Elmer). Quantification was performed by drawing ROIs over each well 
to obtain the average radiance per well (photons/second/mm2/steradian). 
2.2.4 Animal models 
Animals were cared for in accordance with the standards of the Canadian Council on 
Animal Care, and under an approved protocol of the University of Western Ontario’s 
Council on Animal Care (2018-150). NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice 
(n=17) received subcutaneous injections of 1x106 NALM6-tdT-FLuc cells mixed with 50 
ul of Matrigel in their left hind flank. Twenty-one days later, each mouse received an 
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intratumoural injection of 10x106 PFC+ CAR-T cells (n=6), unlabeled CAR-T cells 
(n=3), PFC+ untransduced T cells (n=5), or an equivalent volume of saline (n=3). 
2.2.5 Nuclear magnetic resonance (NMR) 
To evaluate the number of average 19F spins in cells, NMR was performed on samples 
containing 1x106 PFC+ CAR-T cells or PFC+ untransduced T cells. To prepare the 
samples for NMR, the cells were lysed by adding 10 µl Radioimmunoprecipitation assay 
(RIPA) buffer (VWR, Mississauga, CAN), sonicated 3 times, and then underwent 3 
freeze-thaw cycles. The lysate was then placed in an NMR tube with 0.1% trifluoroacetic 
(TFA) acid and heavy water (D2O). 19F NMR measurements were performed using a 
Varian Inova 400 spectrometer (Varian Inc, Palo Alto, USA) as described by Makela et 
al. [23]. 
2.2.6 In Vivo BLI 
BLI was performed on days -1, 5, 10, and 14 post-treatment in all mice. Mice were 
anesthetized with 2% isoflurane in oxygen during imaging sessions. Anesthetized mice 
received an intraperitoneal injection of 100µL of D-luciferin (30mg/mL) and images 
were collected using an IVIS Lumina XRMS scanner for up to 30 minutes. Day -1 
images were used as a baseline for tumour burden to determine treatment response after 
CAR-T cell, T cell, or saline injections. BLI signal was evaluated with ROI analysis 
using LivingImage Software (Perkin Elmer). An ROI was drawn around the whole mouse 
and the total flux (photons/sec) was measured to determine the peak signal in the 30-
minute imaging session. The peak signal for each mouse at each time point was recorded 




2.2.7 In Vivo 19F MRI 
Mice bearing leukemia tumours that received PFC+ CAR-T cells or PFC+ untransduced 
T cells were imaged with 19F MRI on days 1, 3, and 7 post-treatment. Mice were 
anesthetized with 2% isoflurane in oxygen during imaging sessions. 1H and 19F images 
were acquired on a clinical 3T MRI (GE 3T MR750 system, General Electric, ON, CAN) 
using a custom built 4.3 x 4.3 cm2 dual tuned 1H/19F surface coil. In vivo 1H and 19F 
images were both acquired with a 3D balanced steady state free precession (bSSFP) pulse 
sequence. Two reference tubes of known 19F concentration (3.33 x 1016 19F/µL) were 
imaged alongside the mice for quantification purposes. 1H imaging parameters were: field 
of view (FOV) = 60 x 30 mm, matrix size = 150 x 75, slice thickness = 0.4 mm (0.4 x 0.4 
x 0.4 mm3 resolution), flip angle (FA) = 20°, bandwidth (BW) = ±31.25 kHz, repetition 
time (TR)/ echo time (TE) = 12.8/6.4 ms, phase cycles (PC) = 12, total scan time = 9 
minutes. 19F imaging parameters were: FOV = 60 x 30 mm, matrix = 60 x 30, slice 
thickness = 1 mm (1 x 1 x 1 mm3 resolution), FA = 72°, BW = ±10 kHz, TR/TE = 5.6/2.8 
ms and 150 NEX, scan time = 27 mins.  
19F images were analyzed using Horos software. The standard deviation (Sdev) of 
background signal for each 19F image was measured by drawing a region of interest 
(ROI) in an area of background noise. A minimum threshold of 5 times the Sdev was 
used to mask lower amplitude signal and yield a reliable measurement of 19F signal in 
cell pellets, tumors, and reference tubes. This imaging criteria is based on an 19F signal 
with signal-to-noise (SNR) ratio > 5. Total 19F signal in cell pellets, tumors, and reference 
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tubes was calculated as mean 19F signal * volume of ROI. 19F content in cell pellets and 
tumors was determined by comparing the 19F signal measured from these ROIs to the 
signal measured from the reference tubes (3.33 x 1016 19F/µL).  
2.2.8 Histology 
Two mice from the PFC+ CAR-T cell treatment group and the PFC+ untransduced T cell 
treatment group were euthanized via overdose of isoflurane on day 10 post-treatment. 
Their primary tumours were excised, fixed in 4% paraformaldehyde, and cryoprotected 
by passaging through a sucrose gradient of 10%, 20%, and 30%. Samples were then 
frozen in optimal cutting temperature compound using dry ice and 10 µm sections were 
collected using a cryostat (Leica CM350 Cryostat). Tumour sections was stained with 
DAPI and imaged using fluorescence microscopy (EVOS FL Auto 2) to detect GFP 
expressing CAR-T cells. 
2.2.9 Statistics 
Statistics were performed using the GraphPad Prism 8 Software. Unpaired t-tests were 
performed on the in vitro BLI cytotoxicity assay data to assess the difference between the 
cytotoxicity of PFC+ and PFC- CAR-T cells. A simple linear regression was performed 
on the in vitro 19F MRI data to assess the correlation between 19F signal and cell number. 
A two-way ANOVA with multiple comparisons was performed on the in vivo 19F signal 
data to compare between the labeled treatment groups at each time point. A two-way 
ANOVA with Tukey’s multiple comparisons was performed on the in vivo BLI data to 
assess any differences in the treatment responses observed between treatment groups at 





2.3.1 Production and characterization of treatment and target cells  
Figure 2.1a shows a representation of the CD19-CAR-GFP plasmid used to make CD19 
targeting CAR-T cells and the tdT-FLuc plasmid used to make firefly luciferase 
expressing NALM6 cells. Flow cytometry revealed that CAR-T cell populations were 
approximately 68.6% CAR/GFP positive after transduction. Further, the CAR-T cell 
populations were approximately 97% CD3 positive, 67.5% CD4 positive, and 26.1% 
CD8 positive prior to injection. Untransduced T cell populations showed similar 
characteristics with approximately 97% CD3 positive cells, 47.6% CD4 positive cells, 
and 45.5% CD8 positive cells (Fig 2.1c). After labeling the T cell populations with 5 
mg/ml texas red fluorophore-conjugated PFCs overnight, 88.8% of the cells were positive 
for uptake of PFC (Fig 2.1d). On average, the labeled T cell populations contained 
5.116865×1011 19F/Cell. After transduction, 98.7% of NALM6 cells expressed tdT/Fluc 








Figure 2.1: Production and characterization of CAR-T cells and their target cells. 
(a) Diagrams depicting a lentiviral (LV) tdT-FLuc transfer plasmid co-expressing 
the tdTomato fluorescent gene and firefly luciferase (FLuc2) bioluminescence 
reporter gene for the production of NALM6-tdT-FLuc cells and the LV-CD19-
CAR-GFP plasmid co-expressing the CD19 targeted second generation CAR and 
GFP for the production of CD19 CAR-T cells. (b) Merged histograms showing the 
NALM6 cell population before and after transduction with the tdT-FLuc lentivirus. 
(c) Bar graph showing the percent expression of CAR/GFP, CD3, CD4, and CD8 
markers in CD19-CAR-GFP transduced T cell populations and untransduced T cell 
populations (n=3). (d) Merged histograms showing a representative CAR-T cell 







2.3.2 In vitro assessment of PFC labeled CAR-T cells and their 
target cells 
Figure 2.2 shows the in vitro characterization data for the imaging reporters and CAR-T 
cell cytotoxicity. BLI revealed that the NALM6-tdT-Fluc cell line had functional Fluc2 
activity (Fig 2.2a). Cytotoxicity assays showed that co-culture with unlabeled CAR-T 
cells caused an average of 63.6%, 80.5%, and 94.5% Nalm6-tdT-Fluc cell lysis at 
effector to target ratios of 1:4, 1:2, and 1:1, respectively (Fig 2.2a). In comparison, PFC+ 
CAR-T cells caused an average of 43.3%, 73.7%, and 90.0% Nalm6-tdT-Fluc cell lysis at 
effector to target ratios of 1:4, 1:2, and 1:1, respectively. There was no significant 
difference in cytotoxicity between unlabeled and PFC+ CAR-T cells at any effector to 
target ratio (Fig 2.2b). In vitro 19F MRI of PFC+ CAR-T cell pellets showed that pellets 
containing only 12.5% labeled CAR-T cells (2.5x105 PFC+ CAR-T cells) could be 
reliably detected at 3T. Quantification of the 19F spins revealed that there was a strong 




Figure 2.2: In vitro characterization of the PFC labeled CAR-T cells. (a) BLI 
cytotoxicity assay showing the viability of NALM6-tdT-FLuc cells in the presence of 
saline (control), unlabeled CAR-T cells (PFC-), or PFC labeled CAR-T cells (PFC+) 
at increasing effector to target ratios (n=3). (b) Bar graph showing percent lysis of 
the NALM6-tdT-FLuc cells 24 hours after treatment with PFC labeled or unlabeled 
CAR-T cells. (c) 19F MRI of PFC labeled CAR-T cell pellets (2x106 total cells) 
containing decreasing numbers of labeled CAR-T cells (2, 1, 0.5, 0.25, 0.1 (x106) 
cells). (d) Quantification of 19F signal compared to cell number shows a strong 






2.3.3 19F Cellular MRI Detection of PFC-Labeled T cells in Tumor-
Bearing NSG Mice 
In vivo detection of PFC+ CAR-T cells using 3T clinical MRI was assessed after 
intratumoural injections of 10x106 cells into mice bearing subcutaneous Nalm6-tdT-Fluc 
tumours. All mice injected with NALM6-tdT-Fluc cells developed tumours in their left 
hind flanks by day 21 post-injection. Figure 2.3 shows representative 19F images of 
tumour bearing mice after intratumoural injections of either PFC+ CAR-T cells or PFC+ 
T cells. 19F images are overlaid onto 1H images for anatomical reference. In all mice, 19F 
signal was present in the tumour on days 1, 3, and 7 post PFC+ cell injection (Fig 2.3a 
and 2.3b). The 19F MRI data shows that the PFC+ T cells and CAR-T cells were 
accurately injected intratumourally in all of the treated mice and the persistent 19F signal 
suggests that the PFC+ cells remain in the tumour over time. The total number of 19F 
spins for each tumor on days 1, 3, and 7 were quantified and are shown in Figure 2.3c. 
The mean number of 19F spins was not significantly different between PFC+ CAR-T cell 








Figure 2.3: In vivo 19F MRI of leukemia tumour bearing mice treated with 10x106 
PFC labeled CAR-T cells (n=6) or 10x106 PFC labeled untransduced T cells (n=5). 
19F images are overlaid onto 1H images for anatomical reference. 19F signal is 
detected in the tumours over time. Scale bars represent the range of 19F signals. (a) 
Representative images from two PFC labeled CAR-T cell treated mice on days 1, 3 
and 7 post-treatment. (b) Representative images of a PFC labeled untransduced T 
cell treated mouse on days 1, 3, and 7 post-treatment. (c) Quantification shows no 
significant differences of 19F signal over time between PFC+ CAR-T cell and PFC+ 








2.3.4 In vivo BLI of leukemia bearing mice treated with CAR-T 
cells 
To assess whether PFC labeling effected CAR-T cell therapy outcome, BLI images of 
NALM6-tdT-Fluc tumour bearing mice were obtained up to 14 days after intratumoural 
injections of 10x106 PFC+ CAR-T cells (Fig 2.4a), unlabeled CAR-T cells (Fig 2.4b), 
PFC+ T cells (Fig 2.4c), or an equivalent volume of saline (Fig 2.4d). PFC+ and 
unlabeled CAR-T cell treated mice showed decreased BLI signal after treatment. PFC+ T 
cell and saline treated mice showed continuous increases in BLI signal after treatment. 
The total flux from each mouse at each imaging timepoint was quantified and are shown 
in Figure 2.4e. Mice treated with PFC+ CAR-T cells had significantly lower BLI signal 
by day 14 compared to mice treated with PFC+ T cells or saline (p<0.0001, p<0.0001). 
There were no significant differences between the BLI signal in mice treated with saline 
or PFC+ T cells at any time point. Importantly, there were no significant differences in 
BLI signal between mice treated with unlabeled CAR-T cells compared to mice treated 




Figure 2.4: In vivo BLI of firefly luciferase expressing NALM6 tumour bearing mice 
days -1, 5, 10, and 14 post-treatment with intratumoural injections of 10x106 PFC 
labeled CAR-T cells (n=6), unlabeled CAR-T cells (n=3), PFC labeled T cells (n=5), 
or and equivalent volume of saline (n=3). (a) Representative images of a PFC 
labeled CAR-T cell treated mouse showing a decrease in tumour burden over time. 
(b) Representative images of an unlabeled CAR-T treated mouse showing a decrease 
in tumour burden over time. (c) Representative images of a PFC labeled T cell 
treated mouse showing increases in tumour burden over time. (d) Representative 
images of a saline treated mouse showing increases in tumour burden over time. (e) 
Quantitation of BLI signal over time showing significant differences between PFC 
labeled CAR-T cell treated mice compared to PFC labeled T cell and saline treated 
mice on day 14 (P<0.0001 and p<0.0001). There is no significant difference between 





Tumours from mice that received intratumoural injections of PFC+ CAR-T cells or PFC+ 
T cells were excised on day 10 post-treatment and analyzed to detect the presence or 
absence of CAR-T cells. Histological analysis confirmed that GFP positive CAR-T cells 
were still present in PFC+ CAR-T cell treated tumours on day 10 post injection (Fig 











Figure 2.5: Histological analysis of GFP expression in a murine tumour treated with 
PFC+ GFP expressing CAR-T cells or a murine tumour treated with PFC+ 
untransduced T cells. (a) Images showing GFP positive CAR-T cells in the tumour 
treated with PFC+ CAR-T cells 10 days post intratumoural injection. (b) Images 
showing no GFP positive cells in tumours treated with PFC+ untransduced T cells 











2.4 Discussion  
 
CAR-T cell therapies have shown tremendous promise in clinical trials against B cell 
malignancies. Despite these successes, there are still many limitations to overcome 
including overcoming their potential to causes serious side effects and increasing their 
efficacy in some patients with hematological malignancies and patients with solid 
tumours. Studies have shown that intratumoural injections of CAR-T cells may improve 
the treatment outcome in models of solid tumours [24], [25]. One of the main barriers in 
intratumoural treatments is ensuring that the injection is administered accurately to 
tumours that may be different sizes and in different locations across patients. Acquiring 
adequate information on cell location and persistence after injection may improve 
intratumoural treatments by ensuring that each patient receives the therapy in the correct 
location. In this study, we demonstrate that 19F MRI at 3T provides information on PFC 
labeled CAR-T cell location and persistence after injection into mice bearing NALM6-
tdT-FLuc tumours. Importantly, we saw no significant effect on CAR-T cell treatment 
due to PFC labeling.  
Clinical translation of cell tracking requires a safe cell label that can be detected with 
imaging devices that are commonly found in hospitals. PET has been used in 
combination with clinically relevant radiotracers in many studies to track immune cells 
with high sensitivity [10],[26],[27]. Unfortunately, concerns about cost, half-life, and 
radioactive dose may limit longitudinal cell tracking studies using PET [28]. In contrast, 
MRI uses non-ionizing radiation which is ideal for longitudinal cell tracking studies as 
radiation dose is not of concern. For this reason, we chose to use 19F MRI as our imaging 
78 
 
modality and 19F PFCs as our cell label because these are both clinically applicable and, 
in combination, allow for direct cell detection and quantification. CAR-T cells had been 
successfully labeled with PFCs for detection with 19F MRI in the past, but these studies 
used field strengths well above clinical field strengths to enhance 19F signal [18], [19]. In 
addition, these studies used CAR-T cells labeled with PFC nanoemulsions that are not, at 
this time, commercially available nor manufactured in a manner acceptable for human 
use. We demonstrated that functioning CAR-T cells could be detected using 3T clinical 
MRI using a surface coil and SNR optimized bSSFP sequence after labeling with 
commercially available PFC, which is also available in GMP form for clinical translation. 
Additionally, we were able to perform the imaging using a clinically feasible scan time of 
approximately 9 minutes for the 1H scan and 27 minutes for the 19F scan.  
Our phenotyping results for PFC+ CAR-T cells shown in Figure 1, agree with previous 
studies showing that CD8 expressing cells make up approximately 1/3 of the population 
and CD4 expressing cells make up approximately 2/3 of the population [19], [20]. Our 
cell labeling allowed us to image down to 250 000 cells in vitro which agrees with 
previously published results suggesting that thousands of PFC+ cells are needed per 
voxel to achieve detection [23]. Our in vivo imaging of mice treated with PFC+ T or 
CAR-T cells showed that 19F signal could be detected in every tumour on days 1, 3 and 7 
post treatment. Our findings on PFC+ CAR-T cell detection after intratumoural injection 
are similar to recent results published by Chapelin et al. which looked at PFC+ CAR-T 
cells up to day 10 post intratumoural injection in a mouse model of glioma using an 
11.7T MRI scanner [18]. The 19F signal was consistent over time and suggested that the 
CAR-T cells were viable and persisting in the tumour site. We also did not see significant 
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differences between the 19F signal detected in mice receiving PFC+ CAR-T cells 
compared to PFC+ T cells. This is consistent with their work and may be because T cells 
are surviving and remaining in the tumour site in both treatment groups.  
We chose to complement our 19F MRI CAR-T cell detection with BLI to assess treatment 
response in our mice and determine if PFC labeling influenced in vivo CAR-T cell 
cytotoxicity. Our in vitro results showed no significant differences in cytotoxicity 
between labeled and unlabeled CAR-T cells, similar to previous work [18]. In addition, 
previous PFC+ CAR-T cell tracking studies have shown that labeled CAR-T cells cause 
cytotoxicity against glioma in vivo. However, to our knowledge no studies have evaluated 
PFC+ CAR-T cell in vivo cytotoxicity compared to unlabeled CAR-T cell cytotoxicity. 
BLI of luciferase-expressing tumors over time in mice treated with both PFC+ CAR-T 
cells and unlabeled CAR-T cells demonstrated that PFC labeling does not significantly 
affect CAR-T cell in vivo cytotoxicity in this model.  
There are still limitations to our cell detection method including 19F MRI being less 
sensitive compared to clinical imaging modalities such as PET and cell division 
preventing accurate measures of cell number over time [29]. These limitations are 
especially important when working with T cells because they are small and non-
phagocytic which makes them more difficult to label. Nevertheless, in current clinical 
studies testing intratumourally injected CAR-T cells, patients receive up to 1x1010 CAR-
T cells, which is well above the detection limit of 19F MRI [30]. One advantage of 19F 
MRI is that it is quantitative and the number of cells in a given region can be estimated 
using in vitro NMR data to determine the amount of 19F per cell. This method can be used 
to quantify cell numbers early after injection. However, it is important to point out that 
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this method is not as reliable for quantifying CAR-T cell numbers over time, as CAR-T 
cells have been shown to proliferate significantly after CAR interaction with their 
respective antigen [31]. During cell division, the PFC label should be divided between 
daughter cells. If these cells do not remain in the same voxels, this may decrease the 19F 
signal in an individual voxel below the detection limit, which would result in an 
underestimate of the number of CAR-T cells. Moreover, if the cells remain in the same 
voxel this would still underestimate the number of CAR-T cells based on 19F spins. There 
is also the potential for background signal caused by macrophages taking up PFCs that 
are lost when labeled cells die after injection. However, studies indicate that when 
labeled cells die the PFC is most likely broken down and released through the liver and 
then exhaled using the reticuloendothelial system [32]. Considering these limitations, it is 
therefore important to not overinterpret the 19F signal as the number of viable cells at 
extended periods after adoptive transfer, particularly in highly dividing cell populations. 
A complementary imaging tool such as reporter genes, which are passed to daughter 
cells, would allow for both highly sensitive short-term imaging with 19F PFCs and long-
term cell viability imaging with a reporter gene [33], [34]. We are currently exploring the 
usefulness of this combination of cellular imaging technologies for tracking CAR-T cells 
in preclinical cancer models. 
Currently, our system would be useful for detecting CAR-T cells after intratumoural 
injections into easily accessible tumours such as glioblastoma, metastatic colorectal 
cancer, and metastatic breast cancer24,25,31. It would be interesting to try imaging 
intravenously injected CAR-T cells in an animal model at clinical MRI field strengths in 
the future to determine if clinical-field strength imaging of intravenously administered 
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CAR-T cells would be feasible. Future work focusing on the development of larger 
radiofrequency coils for dual 1H and 19F MRI would also help advance this field. 
However, even if this is not feasible due to lack of sensitivity, it will still be valuable to 
continue to explore and develop 19F MRI of PFC-labeled CAR-T cells after intratumoral 
injections. In this case, localized coils with high sensitivity like the one used in our study 
would be valuable.  
Conclusions: We report that PFC+ CAR-T cells can be detected over time with 19F MRI 
using a 3T clinical field strength scanner. In addition, we show that PFC labeling does 
significantly impact the in vivo treatment response of CAR-T cells in this model, as 
shown by longitudinal BLI. 19F MRI is a useful tool for determining the location and 
persistence of CAR-T cells in tumours after localized injection and may have utility for 
tracking systemically administered cells in particular tumor types. This imaging tool may 
be useful for optimizing current CAR-T cell therapies and may have broad applications 
for evaluating emerging CAR-T cell formulations in vivo. 
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3 Summary and Future Work  
This chapter summarizes the experimental findings, limitations, and future work 
associated with this thesis. 
3.1 Discussions and Conclusions 
Despite strong evidence supporting CD19 targeting CAR-T cell therapies as an ideal 
cancer treatment for patients with B cell malignancies, there is still the potential for 
severe side effects and poor treatment responses in some patients1. Optimizing CAR-T 
cell therapies and mitigating their side effects could aid in the widespread clinical 
adaptation of these therapies. Knowledge of CAR-T cell biodistribution and persistence 
after injection is crucial to learn more about their behaviour during side effects and poor 
treatment outcomes. Molecular imaging techniques could complement current clinical 
blood tests to provide real time information on the locations and numbers of CAR-T cells 
in important sites in the body such as tumours or off target organs. In this thesis, 19F MRI 
was used to detect PFC+ CAR-T cells in a mouse model of leukemia. Below is a 
summary of the results found in this study. 
In Chapter 2, mice bearing luciferase expressing human B cell leukemia tumours were 
intratumorally injected with PFC+ CD19 targeting CAR-T cells and imaged over time 
with BLI and 19F MRI. The leukemia cells express CD19 which allows them to be 
targeted by the CD19 targeting CAR-T cells. 19F MRI data was quantified to determine 
the number of 19F spins in each tumour over time. BLI data was analyzed to assess the 
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cancer treatment response in mice administered PFC+ CAR-T cells compared to mice 
that received unlabeled CAR-T cells. The main findings were:  
1. PFC+ CAR-T cells could be detected in tumours up to 7 days after injection using 
a 3 T clinical MR scanner and custom dual tuned surface coil designed for use in 
humans.  
2. Quantification of the BLI data showed that PFC+ CAR-T cells show no 
significant difference in cancer treatment response in vivo compared to unlabeled 
CAR-T cells.  
These findings present important evidence that 19F 3T MRI could be a useful tool to 
detect PFC+ CAR-T cells during clinical trials exploring intratumoural injections of 
CAR-T cells. This method may provide information on the location of adoptively 
transferred cells to ensure that the injection was successfully administered into a tumour 
and that CAR-T cells persist in the tumour during the first week of treatment. In many 
cases, a limitation of 19F MRI is the low sensitivity. In our study, we detected strong 
signal in the tumours even at the latest timepoint of day 7 using a clinically relevant scan 
time highlighting the potential for this method in the clinic. 
There are currently three other papers that have PFC labeled CAR-T cells and detected 
them with 19F NMR or MRI. In 2017, Chapelin et al. established PFC labeling techniques 
for CAR-T cells and ensured that the label did not affect T cell phenotype2. In 2019, 
Hingorani et al. successfully imaged PFC+ CAR-T cells for the first time using 19F MRI 
two hours after an intratumoral injection into mice bearing glioma tumours3. Finally, in 
2021 Chapelin et al. imaged intratumourally administered PFC+ CAR-T cells up to 10 
days post-injection for the first time in a mouse model of glioblastoma4. These studies all 
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contributed important milestones to the implementation of 19F MRI for studying CAR-T 
cell therapies. One limitation that is common to all of these studies is that they relied on 
high field strength MR scanners (e.g., 11.7T) that are currently well above clinical 
standards. The work in this thesis successfully implemented PFC+ CAR-T cell detection 
using a 3T clinical MR scanner and RF surface coil designed for human use for the first 
time. Further, this is the first comparison of PFC labeled CAR-T cell and unlabeled CAR-
T cell cytotoxicity in vivo using BLI, which is important to show before PFC labeling and 
19F MRI could be translated to the clinic. It is our hope that these findings support the use 
of 19F MRI for clinical CAR-T cell tracking to achieve patient specific information on 
CAR-T cell location after adoptive transfer.  
3.2 Challenges and Limitations  
 
3.2.1 COVID-19 Pandemic  
The COVID-19 pandemic was a unique challenge for graduate students over the past 
year. I recognize that the pandemic has had more extreme impacts on other populations 
and that overall, I was lucky to have this stable position with the University during this 
time. It was challenging to complete research activities during the lockdowns. I did not 
have access to the laboratory from Mid-March 2020 until June 2020 which meant that I 
could not make any progress on my project. In addition, access to the laboratory and 
research staff has continued to be reduced since we returned to campus in June-August 
2020 due to strict safety measures put in place to stop the spread of COVID-19. This has 
caused significant delays in the completion of my project, but I was still able to complete 




3.2.2  T cell detection challenges with 19F MRI 
Currently, 19F MRI is less sensitive than many other forms of molecular imaging such as 
iron oxide nanoparticle (ION) imaging with MRI or PET5, 6. The sensitivity of 19F MRI is 
reliant on how well the cells are labeled, the imaging sequence chosen, the MR field 
strength, and the RF coil used7. The uptake of PFC by T cells is lower when compared to 
larger, more endocytic/phagocytic cell populations such as dendritic cells or monocytes8. 
This means that the signal obtained from labeled T cell populations will be lower per cell 
compared to other therapeutic cell populations. In addition, when CAR-T cells are 
activated by cancer cells they proliferate extensively to mount a proper response9. As cell 
division occurs, the PFCs are divided between the daughter cells, diluting the amount of 
label in each cell. This causes the amount of 19F per voxel to decrease over time resulting 
in a decrease in signal over time. Eventually, with cell division, the labeled cells will fall 
below the detection limit of 19F MRI. Regardless, using the commercially available PFC 
CelSense, BSSFP pulse sequence, 3T MRI, and a human dual tuned surface coil we were 
able to clearly detect 10 million PFC+ CAR-T cells over time after an intratumoural 
injection into mice bearing leukemia tumours. Clinical trials using intratumoral or local 
delivery methods for CAR-T cells should expect that they would be able to detect the 




3.2.3 Requirements for translating 19F MRI to the clinic  
Implementing 19F MRI cell tracking in a clinical setting would require specialized 
equipment to perform dual 1H and 19F imaging. Many hospitals already have an MR 
scanner which can be used for these imaging applications, but they would need to obtain 
a dual tuned RF coil for 19F MRI and have multi-nuclear imaging capabilities. In 
addition, the RF coil that was used in this study could easily cover the flank tumours on 
mice without any depth concerns. Unfortunately, as 19F MRI is moved towards patient 
imaging the 4.3cm diameter and depth limitations of the surface coil will reduce the 
number of studies that could be performed to track cell populations in patients. During 
the only clinical trial that used 19F MRI to image labeled cells in patients, they used a 7 
cm diameter surface coil10. They successfully imaged and quantified the number of 
intradermally injected PFC+ dendritic cells in two patients enrolled in a dendritic cell 
vaccine study. This data suggests that clinical imaging of 19F PFCs in subcutaneous 
tumours such as breast cancer or prostate cancer should be possible.  
 
In addition, there has still not been a study to determine whether intravenously (IV) 
injected PFC labeled CAR-T cells can be detected at clinical MR field strengths. As most 
clinical trials administer CAR-T cells IV, it is important to determine if it is possible to 
detect CAR-T cells as they traffic to different locations in the body following this 
injection route. Imaging at 3 T would limit the sensitivity of 19F MRI compared to higher 
field strength imaging, but the study in this thesis showed that as few as 2.5x105 cells 
could be detected in vitro.  In most studies, between 1x106-1x108 CAR-T cells are 
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injected per kg of body weight into patients which should improve the chances of 
detecting cells that traffic to certain locations in the body.  
Finally, the lower sensitivity of 19F MRI may require a higher number of excitations 
(NEX) to be used during an imaging session leading to longer scan times. Most current 
MRI scan times for patients are 30 to 40 minutes to avoid patient discomfort11. In our 
study, the pre-clinical scan times were 9 minutes for the 1H scan followed by 27 minutes 
for the 19F scan. This would be feasible in the clinic but as 19F MRI is moved towards 
patients they may need to increase these scan times to accommodate for the depth of the 
PFCs in the body and the RF coil that is being used.  
 
3.2.4 Quantification Inaccuracies  
 
As mentioned in chapter 1 of this thesis, PFC labels are taken up by cells through 
endocytosis and held in the cytoplasm as long as the cell remains viable12. Unfortunately, 
when cell death occurs the labeled cell can be taken up by macrophages and persist in 
tissues leading to background signal. This phenomenon is known as “bystander cell 
uptake” and can cause false positives in 19F images. Although this cannot be avoided, 
Fink et al. have previously confirmed that the 19F signal in their model was being 




In addition to signal accuracy concerns, there are also limitations associated with 
quantifying the number of cells that are detected in an 19F image. As described in chapter 
1, an advantage of 19F MRI is that it is quantitative and can be used to determine the 
number of labeled cells in a subject.  Most studies that have used 19F MRI to track ex 
vivo PFC+ cells have used information from 19F NMR and the signal obtained from 19F 
images to determine the number of cells in a given region. This data may be accurate at 
early imaging timepoints, especially if the cells do not divide or divide very slowly. 
Unfortunately, with cell populations like CAR-T cells, activation causes extensive 
proliferation and dilution of the PFC label. This leads to a decrease in detected 19F signal 
over time which would indicate that there were fewer cells in a given location. In reality, 
there would in fact be many more cells in the body over time due to CAR-T cell 
expansion. For this reason, 19F MRI cannot accurately be used to quantify the number of 
CAR-T cells in a tumour over time. Other groups have still used 19F MRI cell 
quantification to their advantage by determining the accuracy of their intratumoural 
injections immediately following adoptive transfer. Hingorani et al. for example 
determined that they could detect approximately 100% of the cells that they injected 2 
hours after injection into a mouse model of glioma using 19F MRI cell quantification14.  
 
3.3 Future work  
 
Future work will use 19F MRI cell detection to study CAR-T cell location and persistence 
in animal solid tumour models such as breast cancer. Additionally, future work will look 
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into combined 19F MRI and reporter gene-based CAR-T cell tracking to gain more 
information on CAR-T cell behaviour in treatment models and determine the best method 
for clinical cell detection.  
 
 
3.3.1 Explore 19F MRI for intratumourally injected cancers such as 
breast or prostate cancer 
Intratumoural or local delivery of CAR-T cells has been proposed as a method to improve 
the efficacy of CAR-T cell therapies against solid tumours. Multiple pre-clinical studies 
have showed that local delivery of CAR-T cells is an effective method for treating 
tumours and may even improve the therapeutic outcome in animal models compared to 
other injection methods15-17. In addition, there are clinical trials underway to test 
intratumorally injected CAR-T cells in patients with breast cancer and head and neck 
cancer and intracranially injected CAR-T cells in patients with brain cancer18,19. 
Unfortunately, studies have noted that local delivery is more difficult than IV delivery as 
tumours may be different sizes and in different locations making it harder to accurately 
inject the therapy20. An inaccurate injection may have large implications on the efficacy 
of the treatment and the validity of efficacy studies in both pre-clinical and clinical trials. 
In the work presented in this thesis, we were able to demonstrate that CAR-T cells can be 
efficiently labeled with PFC and detected in leukemia tumours over time after 
intratumoural injections. Future work will look at using 19F MRI to detect CAR-T cells in 
relevant solid tumour models such as breast cancer or breast cancer brain metastases. The 
use of 19F MRI in studies testing the efficacy of intratumourally injected CAR-T cells 
would provide important information on the location and persistence of CAR-T cells in 
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the tumours. It could also be used as a metric to ensure that the intratumoural injections 
are accurate and successfully reach the targeted location in the body. This information 
may be useful for determining why some subjects do not respond to CAR-T cells. 
Additionally, it may help in determining which injection route is best for each cancer 
type that is being targeted by the therapy.  
 
3.3.2 Dual 19F and reporter gene-based cell tracking of CAR-T 
cells using MRI  
Reporter gene-based imaging is valuable for studying highly proliferative cell 
populations as it relies on stable expression of a reporter gene. Stable reporter gene 
expression allows for longitudinal cell tracking because the reporter gene is passed onto 
daughter cells during cell division, leading to increased signal as cells proliferate. In 
addition, by co-expressing CARs and reporter genes in the same construct, reporter genes 
can be introduced to T cells using the same protocols that are already in place to generate 
current CAR-T cell therapies in the clinic. Many groups have started to employ reporter 
gene-based imaging methods to try to circumvent the signal loss that occurs with labels 
during cell division21-23. Wu et al. developed a human derived MRI reporter gene called 
organic anion transporting polypeptide 1B3 (OATP1B3) that can be used in combination 
with the clinically approved contrast agent gadolinium ethoxybenzyl 
diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)24. This method of imaging may be 
able to track dividing cells for longer periods of time due to stable gene expression. Using 
this cell detection technique in CAR-T cells in combination with 19F MRI will provide 
both short term and long-term information on cell location, viability, and proliferation 
95 
 
using non-invasive imaging. We posit that this will also be a valuable technique to 
compare 19F MRI of PFC labeled cells against OATP1B3 reporter gene imaging of 
engineered cells. All together, these imaging techniques will provide more information 
on CAR-T cell behaviour after injection that may provide insight into making safer and 
more effective CAR-T cell therapies. Additionally, these techniques will get us closer to 
clinical cell tracking ventures.   
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